Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Thromb Haemost 2011; 105(S 06): S1-S2
DOI: 10.1160/THS11-03-0151
DOI: 10.1160/THS11-03-0151
Thrombosis and Haemostasis Supplement
Education in atherothrombosis
Further Information
Publication History
Received:
06 March 2011
Accepted after major revision:
08 March 2011
Publication Date:
06 December 2017 (online)
-
References
- 1 Collier J. Doctors, patients, and the pharmaceutical industry. Br Med J 2009; 338: b443.
- 2 House of Commons Health Committee.. The influence of the pharmaceutical industry. Fourth Report of Session 2004–05 2005; Available at: www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/42/42.pdf.
- 3 Psaty BM. Conflict of Interest, Disclosure, and Trial Reports. J Am Med Assoc 2009; 301: 1477-1479.
- 4 Foster CJ, Prosser DM, Agans JM. et al. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 2001; 107: 1591-1598.
- 5 Andre P, Delaney SM, LaRocca T. et al. P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest 2003; 112: 398-406.
- 6 Evans DJW, Jackman LE, Chamberlain J. et al. The platelet P2Y12 receptor influences the vessel wall response to arterial injury and thrombosis. Circulation 2009; 119: 116-122.
- 7 Patil SB, Jackman LE, Francis SE. et al. Ticagrelor effectively and reversibly blocks murine platelet P2Y12-mediated thrombosis and demonstrates requirement for sustained P2Y12 inhibition to prevent subsequent neointima. Arterioscler Thromb Vasc Biol 2010; 30: 2385-2391.
- 8 Hechler B, Gachet C. Comparison of two murine models of thrombosis induced by atherosclerotic plaque injury. Thromb Haemost 2011; (Suppl. 01) S3-S12.
- 9 Nurden AT. Platelets, Inflammation and Tissue Regeneration. Thromb Haemost 2011; (Suppl. 01) S13-S33.
- 10 Badimon L, Storey RF, Vilahur G. Update on lipids, inflammation and atherothrombosis. Thromb Haemost 2011; (Suppl. 01) S34-S42.
- 11 Hess K, Grant P. Inflammation and thrombosis in diabetes. Thromb Haemost 2011; (Suppl. 01) S43-S54.
- 12 Ferreiro JL, Gómez-Hospital JA, Angiolillo DJ. Platelet Abnormalities in Diabetes Mellitus. Diabetes Vasc Dis Res 2010; 7: 251-259.
- 13 Ferreiro JL, Cequier AR, Angiolillo DJ. Antithrombotic Therapy in Patients with Diabetes Mellitus and Coronary Artery Disease. Diabetes Vasc Dis Res 2010; 7: 274-288.
- 14 Alzahrani SH, Ajjan RA. Coagulation and fibrinolysis in diabetes. Diabetes Vasc Dis Res 2010; 7: 260-273.
- 15 Storey RF. What drives thrombogenesis despite antiplatelet therapy in diabetes mellitus?. Diabetes Vasc Dis Res 2010; 7: 249-250.
- 16 Tentzeris I, Siller-Matula J, Farhan S. et al. Non-genetic causes of platelet function variability. Thromb Haemost 2011; (Suppl. 01) S60-S66.
- 17 Yukhanyan L, Freynhofer M, Siller-Matula J, Schrör K, Huber K. Genetic variability in response to clopidogrel therapy and its clinical implications. Thromb Haemost 2011; (Suppl. 01) S55-S59.
- 18 Cattaneo M. Congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate. Thromb Haemost 2011; (Suppl. 01) S67-S74.
- 19 Storey RF. Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors. Thromb Haemost 2011; (Suppl. 01) S75-S81.